The risk of developing dementia may be double what was previously thought. But there are things the U.S. can do to help fight ...
Recent headlines suggest that up to 42% of people ages 55 and older face an eventual dementia diagnosis. But some experts have a follow-up message: Risk isn't the same as destiny, and there are ways ...
Researchers at the University of Kentucky's Sanders-Brown Center on Aging are at the forefront of advancing dementia research ...
Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the ...
The search for answers to Alzheimer's disease and other neurodegenerative disorders remains one of the most pressing goals in brain research. Maciej J. Stawikowski, Ph.D., an assistant professor of ...
Kyung Bo Kim discovered compounds that improved cognitive function regardless of amyloid plaque buildup — an encouraging sign ...
The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...
PsyPost on MSN3d
Focused ultrasound shows promise in treating Alzheimer’s by reducing amyloid plaquesA new study published in the Journal of Neurosurgery highlights the potential of focused ultrasound technology in treating ...
New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according to a report. The report by GlobalData, a data and analytics company, showed ...
The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback